title: [Is the validated ICIQ-SF suitable for evaluation of OAB patients? A data analysis of intravesicular botulinum toxin therapy].
abstract: BACKGROUND
  The following data analysis studied the aspects of patient satisfaction following onabotulinum toxin A (BTX-A) treatment including modification of certain parameters, such as frequency of micturition and the use of pads and in particular, the applicability of the international consultation on incontinence questionnaire short form (ICIQ-SF) and the urgency perception scale (UPS) in patients with an overactive bladder (OAB).
  
  
  METHODS
  In this study 40 female patients were questioned in the form of validated questionnaires (extended ICIQ-SF and UPS) before and after being injected with 300 IU of BTX-A in each detrusor muscle. The average age of the patients was 66 years. All patients experienced anticholinergic refractory, non-neurogenic OAB.
  
  
  RESULTS
  The recommendation rate and related patient satisfaction was 82.5 %. A significant decrease in the frequency of micturition by 50.9 % (p < 0.01) was reported as well as a significant reduction in the use of pads by 66.7 % (p < 0.01). The average number of ICIQ-SF points could be significantly (p < 0.01) reduced via BTX-A from 15.9 to 7.3. Moreover, BTX-A demonstrated a significant improvement in the urgency to urinate, which was illustrated through the UPS.
  
  
  CONCLUSIONS
  Treatment with BTX-A achieves significant improvements in female patients with anticholinergic refractory OAB with regard to the individual symptoms of OAB (e.g. pollakisuria, nocturia, undesired urination and urgency). The use of the ICIQ-SF as the only questionnaire in OAB diagnostics proved to be unsuitable as it does not include female patients with dry OAB to an adequate degree. A combination of various validated questionnaires, such as ICIQ-SF and UPS, proved to be useful.
authors.affiliation: Klinik und Poliklinik für Urologie, Uniklinik Köln, Kerpener Straße 62, 50937, Köln-Lindenthal, Deutschland, jenny.paas@uk-koeln.de.
authors.forename: J
authors.initials: J
authors.lastname: Paas
authors.forename: N
authors.initials: N
authors.lastname: Muthen
authors.forename: V
authors.initials: V
authors.lastname: Weiß
authors.forename: S
authors.initials: S
authors.lastname: Wille
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000008:administration & dosage; D017063:Outcome Assessment, Health Care / Q000379:methods* / Q000592:standards*; D017060:Patient Satisfaction; D011788:Quality of Life / Q000523:psychology*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D011795:Surveys and Questionnaires / Q000592:standards; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D014572:Urology / Q000592:standards
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A